BioAge Labs 3Q 2026: Revenue $298K, EPS ($0.73) — 10-Q Summary

BioAge Labs’ collaboration revenue fell 85% year over year, while its net loss widened 66%. Revenue was reduced by a $1.7 million cumulative catch-up adjustment tied to an expanded Novartis research program; higher BGE-102 clinical-trial and manufacturing costs drove increased research and developm…